Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Find out various ways to enhance your cash back while grocery shopping. Boost your savings effortlessly with these tips.
28,120 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
This guide compares two popular bond ETFs—Fidelity Bond ETF (FIGB) and IEI—focusing on yield, fees, and risk. Learn p...
With the Fed continuing its easing drive in 2026, savers face a key choice between a HYSA and a CD. This report break...
Palantir sits around $130 as Michael Burry’s $46 valuation challenge re-emerges, forcing a sharper look at growth, ma...
Palantir just beat earnings, yet its stock fell in after-hours trading as traders priced in slower growth and macro h...
Two leaders, two paths: Nuscale Power’s SMRs and Nano Nuclear Energy’s microreactors. This guide breaks down commerci...
Bitmine reports a week of heavy ETH buying, boosting its holdings to about 4.59% of all ETH. The move comes alongside...
VGIT remains a stable Treasury income option as yields swing with policy signals. This report analyzes how duration r...
In the first five months of 2026, luxury buyer interest doubles in the U.S. luxury market, with buyers favoring large...
Analysts released a wave of Friday calls on major names, lifting some stocks and easing others as markets digest the ...
A year-by-year calculation shows how much capital you need to generate $3,000 a month via dividends, with tradeoffs a...
A top exec recently sold a sizable block of Freshpet shares. This article breaks down what insider selling means, how...